… For patients with metastatic NSCLC harboring EGFR mutation, EGFR tyrosine kinase
inhibitors (TKIs) have been the standard first-line treatment, 5 ,6 and accumulating evidence …

… open-label clinical study of a total of 106 treatment-naïve patients with metastatic EGFR
mutation… Eligible patients were required to have a deletion in EGFR exon 19 or L858R, L861Q, or …

… We did an open label, phase 3 study (WJTOG3405) with recruitment between March 31, …
recurrence harbouring EGFR mutations (either the exon 19 deletion or L858R point …

… TKI therapy could be an appropriate adjuvant therapy in EGFR mutation-… -EGFR (NCT02193282)
and WJOG6410L (UMIN000006252), are awaited to confirm the role of adjuvant EGFR-…

… Tumors harboring EGFR mutations are highly sensitive to EGFR … , five EGFR TKIs are
approved for the treatment of EGFR mutation-positive NSCLC: the first-generation reversible EGFR …

… EGFR mutations were detected by using an amplification mutation refractory system with an
EGFR mutation … considered EGFR mutation positive if at least one of 29 EGFR mutations (…

… were screened for exon19 microdeletions and exon21 L858R EGFR mutations using the
companion diagnostic EGFR test. EGFR mutation-positive, locally advanced or metastatic lung …

… All patients must have advanced NSCLC with activating EGFR mutation and must have
progressed on at least 1 prior EGFR inhibitor. Starting from 20 mg QD continuous dosing, dose …

… A was superior to first-line pemetrexed/cisplatin in a global phase III trial (LUX-Lung 3) in
EGFR M+ NSCLC. This study compared the safety and efficacy of first-line A with GC in EGFR M…

… Preclinical data suggest that EGFR can mediate resistance in … EGFR. Therefore, combined
inhibition of the BRAF pathway (with D or D + T and with anti-EGFR agent P) to prevent EGFR-…